PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM For cancer therapy: Somatuline Autogel (lanreotide acetate)

Please note that the patient AND physician must complete this form. All fields are mandatory and must be

completed. Incomplete forms may result in your application being declined. Please retain a copy of this form for your records.

Instructions:

- 1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.
- 2. The patient/plan member must complete section A.
- **3.** Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
- 4. Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to 1-866-840-1509.
- 5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

A. Information to be Completed by the Patient				
Member's or Recipient's Name	Drug Card Number			
	·			
Patient's Name	Patient's Date of Birth (DD/MMM/YYYY) Relationship to Member/Rec			
	//	🗅 Member 🗅 Spouse 🗅 Dependent		

Please allow two business days for a response once all information is received and complete. Notification of the results of this request will occur Monday to Friday between 9 a.m. and 4 p.m. Eastern Time.

Please provide contact information and indicate **ONE** method of preferred contact for notification of the results:

E-mail	Call me (and leave a message if I'm not there):	□ Fax me at:
Contact my pharmacy Pharmacy Name:		Pharmacy Phone Number:

I certify that the information provided by me is true, correct and complete to the best of my knowledge. I authorize my insurance company, TELUS Health (a service provider of my insurance company), their authorized representatives, agents and service providers to use and exchange this information needed for underwriting, administration and paying claims with any person or organization who has relevant information pertaining to this claim including health professionals, institutions and investigative agencies in the event of an audit. I authorize my insurance company and/or TELUS Health (a service provider of my insurance company) to contact any licensed physician, institution, pharmacy or person who has any records or knowledge of me or my health with respect to this submitted claim.

SIGNATURE OF PATIENT/PARENT/LEGAL GUARDIAN _____

Date: (DD/MMM/YYYY): ____/ ____/

Tor cancer therapy. Joinaturne	Autoget (tull eotide ace			
B. Information to be Completed by Prescribing Physician				
Drug Name	Strength	Dose		
Somatuline Autogel (lanreotide acetate)				
conditions listed below and if the patient does government mandated program. If the patient program, the prior authorization program, as pa primary plan. If "None of the above criteria" is Quebec plan members, please refer to the RA	t is covered under another dra art of your drug benefits, may indicated, the patient will no	ug plan or government mandated cover the portion not paid for by the ot be eligible for reimbursement. For		
Eligibility Criteria				
Please indicate if the patient satisfies the followin	g criteria:			
Acromegaly (74107003) □ The patient: □ Is ≥ 18 years of age; AND □ Has a diagnosis of acromegaly, AN □ Has a high pretreatment IGF-1 lev AND		ed on the laboratory reference range,		

- □ Has an elevated growth hormone (GH) level defined as a GH level ≥ 1 mg/L following an oral glucose tolerance test (OGTT), AND
- □ Has had inadequate response to, or cannot be treated with a dopamine agonist (e.g. bromocriptine mesylate or cabergoline) at maximally tolerated doses, AND
- Has had an inadequate response to, or cannot be treated with surgery and/or radiotherapy, AND
- □ The prescriber is an endocrinologist, oncologist or other specialist experienced in the treatment of acromegaly.

Enteropancreatic Neuroendocrine Tumours (T990000095)

- □ The patient:
 - \Box is \geq 18 years of age; AND
 - □ Has a diagnosis of enteropancreatic neuroendocrine tumour, AND
 - □ Has stable disease by RECIST criteria (< 20% growth) over 12 to 24 weeks, AND
 - □ Has Grade 1 or a subset of Grade 2 (equivalent to Ki67 marker score of < 10%) unresectable, locally advanced or metastatic disease, AND
- □ The prescriber is an oncologist or other specialist experienced in the treatment of enteropancreatic neuroendocrine tumours.

Carcinoid Syndrome (35868009)

□ The patient:

- □ Is \geq 18 years of age; AND
- □ Has a diagnosis of carcinoid syndrome.

OR

□ None of the above applies

Relevant additional information _

Physician Information					
Physician's Name	License Number	Telephone Number	Fax Number		

Eligibility Criteria					
Address		City	Province		Postal Code
Physician's Signature		Date: (DD/MMM/YYYY)			
			/	/	